JLL Partners Forms New Pharma Firm With Royal DSM In $2.6 Billion Deal
Tue, 19 Nov 2013 00:00:00 GMT
21 Partners agrees to acquire Synerlab from Ardian
Tue, 19 Nov 2013 16:21:10 GMT
European private equity firm 21 Partners said Tuesday that it has agreed to buy Synerlab from investment firm Ardian. No financial terms were disclosed. The transaction will be done in partnership with Synerlab's management team. Also, Ardian will subsequently reinvest in Synerlab. Based in France. Synerlab is a pharmaceutical contract manufacturing firm.
The post 21 Partners agrees to acquire Synerlab from Ardian appeared first on peHUB.
Can’t make it to #DHC13? Follow these 11 speakers on Twitter
Thu, 14 Nov 2013 14:02:41 GMT
It’s been about one year since the launch of the New York Digital Health Accelerator. Since then, Web MD acquired one member, Avado, and Cureatr raised $5.7 million. New York...
Oxygen Biotherapeutics, Inc. Closes the Acquisition Of Assets Related To Levosimendan, Taps New CEO
Thu, 14 Nov 2013 00:00:00 GMT
PsiOxus Therapeutics Limited Cancer-Wasting Drug Better Than Placebo In Phase 2 Study
Wed, 13 Nov 2013 00:00:00 GMT
Johnson & Johnson, Pharmacyclics, Inc. Breakthrough Drug Wins FDA Approval
Thu, 14 Nov 2013 00:00:00 GMT
PRA to acquire CRI Lifetree, boosting global phase I presence
Wed, 13 Nov 2013 09:01:00 GMT
PRA, a CRO based in Raleigh, N.C., intends to acquire privately held CRI Lifetree, a research organization that focuses on early stage, patient population studies.
Grifols to acquire Novartis blood transfusion diagnostics unit for $1.675 billion
Mon, 11 Nov 2013 16:42:26 GMT
Novartis announced a definitive agreement to divest its blood transfusion diagnostics unit to Grifols for $1.675 billion. This transaction, requiring customary regulatory approvals, is expected to be completed in the first half of 2014.
Catalent acquires Relthy, expands South American operations
Fri, 11 Oct 2013 13:04:29 GMT
Catalent Pharma Solutions, a global provider of drug development solutions and advanced delivery technologies, has acquired Relthy Laboratórios in Brazil. Catalent will expand its operations in Brazil, currently the sixth largest pharmaceutical market in the world, to provide customers in Latin America with access to drug delivery technologies. The deal will see Catalent further extend its presence in high growth, emerging markets, having recently announced its expansion into China with softgel and clinical trial supply operations.
McKesson to acquire Celesio for $8.3 billion
Mon, 28 Oct 2013 14:34:30 GMT
McKesson, a North American healthcare services and information technology company, has signed an agreement to acquire a majority stake in Celesio, an international wholesale and retail company and provider of logistics and services to the pharmaceutical and healthcare sectors, for $32 per share and to launch parallel voluntary public tender offers for the remaining publicly-traded shares and outstanding convertible bonds of Celesio. The offer price represents a 39% premium over the three-month volume weighted average price prior to the market speculation that began Oct. 8. The total transaction, including the assumption of Celesio’s outstanding debt, is valued at approximately $8.3 billion.